Urovant Sciences is a biopharmaceutical company focused on developing novel therapies for urologic conditions. The Company's lead therapeutic candidate is vibegron (RVT-901), an investigational oral β3-adrenergic agonist being developed for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
|HQ||Irvine, CA, US||Map|
Net income (FY, 2020)
Market capitalization (1-Apr-2021)
Closing stock price (1-Apr-2021)
|USD||Q1, 2018||Q1, 2019||Q2, 2019||Q3, 2019||Q1, 2020||Q2, 2020||Q3, 2020|
Depreciation and Amortization
Cash From Operating Activities
Urovant Sciences has 157 Twitter Followers. The number of followers has increased 8.9% month over month and increased 23.6% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Urovant Sciences founded?
Urovant Sciences was founded in 2016.
Who are Urovant Sciences key executives?
Urovant Sciences's key executives are Jim Robinson, Cornelia Haag-Molkenteller and Walt Johnston.
How many employees does Urovant Sciences have?
Urovant Sciences has 39 employees.
Who are Urovant Sciences competitors?
Competitors of Urovant Sciences include Novartis, Pfizer and Takeda Pharmaceutical.
Where is Urovant Sciences headquarters?
Urovant Sciences headquarters is located at 5281 California Ave #100, Irvine.
Where are Urovant Sciences offices?
Urovant Sciences has offices in Irvine and Basel.
How many offices does Urovant Sciences have?
Urovant Sciences has 2 offices.
Receive alerts for 300+ data fields across thousands of companies